68Ga‐DOTATATE Positron Emission Tomography‐Computed Tomography Quantification Predicts Response to Somatostatin Analog Therapy in Gastroenteropancreatic Neuroendocrine Tumors.

MLA

Lee, Hwan, et al. “68Ga‐DOTATATE Positron Emission Tomography‐Computed Tomography Quantification Predicts Response to Somatostatin Analog Therapy in Gastroenteropancreatic Neuroendocrine Tumors.” Oncologist, vol. 26, no. 1, Jan. 2021, pp. 21–29. EBSCOhost, https://doi.org/10.1634/theoncologist.2020-0165.

APA

Lee, H., Eads, J. R., & Pryma, D. A. (2021). 68Ga‐DOTATATE Positron Emission Tomography‐Computed Tomography Quantification Predicts Response to Somatostatin Analog Therapy in Gastroenteropancreatic Neuroendocrine Tumors. Oncologist, 26(1), 21–29. https://doi.org/10.1634/theoncologist.2020-0165

Chicago

Lee, Hwan, Jennifer R. Eads, and Daniel A. Pryma. 2021. “68Ga‐DOTATATE Positron Emission Tomography‐Computed Tomography Quantification Predicts Response to Somatostatin Analog Therapy in Gastroenteropancreatic Neuroendocrine Tumors.” Oncologist 26 (1): 21–29. doi:10.1634/theoncologist.2020-0165.